A Calsequestrin Cis-Regulatory Motif Coupled to a Cardiac Troponin T Promoter Improves Cardiac Adeno-Associated Virus Serotype 9 Transduction Specificity

Kyle Chamberlain, Jalish M. Riyad, Tyrone Garnett, Erik Kohlbrenner, Ananda Mookerjee, Firas Elmastour, Ludovic Benard, Jiqiu Chen, Thierry Vandendriessche, Marinee K. Chuah, Ali J. Marian, Roger J. Hajjar, Priyatansh Gurha, Thomas Weber

Research output: Contribution to journalArticle

  • 1 Citations

Abstract

Adeno-associated virus serotype 9 (AAV9) is an efficient vector for gene transfer to the myocardium. However, the use of ubiquitous promoters, such as the cytomegalovirus (CMV) promoter, can result in expression of the transgene in organs other than the heart. This study tested if the efficiency and specificity of cardiac transcription from a chicken cardiac troponin T (TnT) promoter could be further increased by incorporating a cardiomyocyte-specific transcriptional cis-regulatory motif from human calsequestrin 2 (CS-CRM4) into the expression cassette (Enh.TnT). The efficiency of luciferase expression from the TnT and Enh.TnT constructs was compared to expression of luciferase under the control of the CMV promoter in both adult and neonatal mice. Overall, expression levels of luciferase in the heart were similar in mice injected with AAV9.TnT.Luc, AAV9.Enh.TnT.Luc and AAV9.CMV.Luc. In contrast, expression levels of luciferase activity in nontarget organs, including the liver and muscle, was lower in mice injected with the AAV9.TnT.Luc compared to AAV9.CMV.Luc and was negligible with AAV9.Enh.TnT. In neonates, in organs other than the heart, luciferase expression levels were too low to be quantified for all constructs. Taken together, the data show that the AAV9 Enh.TnT constructs drives high levels of expression of the transgene in the myocardium, with insignificant expression in other organs. These properties reduce the risks associated with the AAV9-mediated expression of the therapeutic protein of interest in nontarget organs. The excellent cardiac specificity should allow for the use of higher vector doses than are currently used, which might be essential to achieve the levels of transgene expression necessary for therapeutic benefits. Taken together, the findings suggest that the Enh.TnT transcription unit is a potentially attractive tool for clinical cardiac gene therapy in adults.

LanguageEnglish
Pages927-937
Number of pages11
JournalHuman Gene Therapy
Volume29
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Calsequestrin
Dependovirus
Troponin T
Luciferases
Cytomegalovirus
Transgenes
Myocardium
Serogroup
Cardiac Myocytes
Genetic Therapy
Chickens

Keywords

  • AAV9
  • calsequestrin enhancer
  • cardiac tropism
  • cardiac-specific cis-regulatory motif
  • CMV
  • troponin T

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

A Calsequestrin Cis-Regulatory Motif Coupled to a Cardiac Troponin T Promoter Improves Cardiac Adeno-Associated Virus Serotype 9 Transduction Specificity. / Chamberlain, Kyle; Riyad, Jalish M.; Garnett, Tyrone; Kohlbrenner, Erik; Mookerjee, Ananda; Elmastour, Firas; Benard, Ludovic; Chen, Jiqiu; Vandendriessche, Thierry; Chuah, Marinee K.; Marian, Ali J.; Hajjar, Roger J.; Gurha, Priyatansh; Weber, Thomas.

In: Human Gene Therapy, Vol. 29, No. 8, 01.08.2018, p. 927-937.

Research output: Contribution to journalArticle

Chamberlain, K, Riyad, JM, Garnett, T, Kohlbrenner, E, Mookerjee, A, Elmastour, F, Benard, L, Chen, J, Vandendriessche, T, Chuah, MK, Marian, AJ, Hajjar, RJ, Gurha, P & Weber, T 2018, 'A Calsequestrin Cis-Regulatory Motif Coupled to a Cardiac Troponin T Promoter Improves Cardiac Adeno-Associated Virus Serotype 9 Transduction Specificity' Human Gene Therapy, vol. 29, no. 8, pp. 927-937. https://doi.org/10.1089/hum.2017.188
Chamberlain, Kyle ; Riyad, Jalish M. ; Garnett, Tyrone ; Kohlbrenner, Erik ; Mookerjee, Ananda ; Elmastour, Firas ; Benard, Ludovic ; Chen, Jiqiu ; Vandendriessche, Thierry ; Chuah, Marinee K. ; Marian, Ali J. ; Hajjar, Roger J. ; Gurha, Priyatansh ; Weber, Thomas. / A Calsequestrin Cis-Regulatory Motif Coupled to a Cardiac Troponin T Promoter Improves Cardiac Adeno-Associated Virus Serotype 9 Transduction Specificity. In: Human Gene Therapy. 2018 ; Vol. 29, No. 8. pp. 927-937.
@article{9209cfaf8fd74b1188acec75f4ee5e44,
title = "A Calsequestrin Cis-Regulatory Motif Coupled to a Cardiac Troponin T Promoter Improves Cardiac Adeno-Associated Virus Serotype 9 Transduction Specificity",
abstract = "Adeno-associated virus serotype 9 (AAV9) is an efficient vector for gene transfer to the myocardium. However, the use of ubiquitous promoters, such as the cytomegalovirus (CMV) promoter, can result in expression of the transgene in organs other than the heart. This study tested if the efficiency and specificity of cardiac transcription from a chicken cardiac troponin T (TnT) promoter could be further increased by incorporating a cardiomyocyte-specific transcriptional cis-regulatory motif from human calsequestrin 2 (CS-CRM4) into the expression cassette (Enh.TnT). The efficiency of luciferase expression from the TnT and Enh.TnT constructs was compared to expression of luciferase under the control of the CMV promoter in both adult and neonatal mice. Overall, expression levels of luciferase in the heart were similar in mice injected with AAV9.TnT.Luc, AAV9.Enh.TnT.Luc and AAV9.CMV.Luc. In contrast, expression levels of luciferase activity in nontarget organs, including the liver and muscle, was lower in mice injected with the AAV9.TnT.Luc compared to AAV9.CMV.Luc and was negligible with AAV9.Enh.TnT. In neonates, in organs other than the heart, luciferase expression levels were too low to be quantified for all constructs. Taken together, the data show that the AAV9 Enh.TnT constructs drives high levels of expression of the transgene in the myocardium, with insignificant expression in other organs. These properties reduce the risks associated with the AAV9-mediated expression of the therapeutic protein of interest in nontarget organs. The excellent cardiac specificity should allow for the use of higher vector doses than are currently used, which might be essential to achieve the levels of transgene expression necessary for therapeutic benefits. Taken together, the findings suggest that the Enh.TnT transcription unit is a potentially attractive tool for clinical cardiac gene therapy in adults.",
keywords = "AAV9, calsequestrin enhancer, cardiac tropism, cardiac-specific cis-regulatory motif, CMV, troponin T",
author = "Kyle Chamberlain and Riyad, {Jalish M.} and Tyrone Garnett and Erik Kohlbrenner and Ananda Mookerjee and Firas Elmastour and Ludovic Benard and Jiqiu Chen and Thierry Vandendriessche and Chuah, {Marinee K.} and Marian, {Ali J.} and Hajjar, {Roger J.} and Priyatansh Gurha and Thomas Weber",
year = "2018",
month = "8",
day = "1",
doi = "10.1089/hum.2017.188",
language = "English",
volume = "29",
pages = "927--937",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "8",

}

TY - JOUR

T1 - A Calsequestrin Cis-Regulatory Motif Coupled to a Cardiac Troponin T Promoter Improves Cardiac Adeno-Associated Virus Serotype 9 Transduction Specificity

AU - Chamberlain, Kyle

AU - Riyad, Jalish M.

AU - Garnett, Tyrone

AU - Kohlbrenner, Erik

AU - Mookerjee, Ananda

AU - Elmastour, Firas

AU - Benard, Ludovic

AU - Chen, Jiqiu

AU - Vandendriessche, Thierry

AU - Chuah, Marinee K.

AU - Marian, Ali J.

AU - Hajjar, Roger J.

AU - Gurha, Priyatansh

AU - Weber, Thomas

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Adeno-associated virus serotype 9 (AAV9) is an efficient vector for gene transfer to the myocardium. However, the use of ubiquitous promoters, such as the cytomegalovirus (CMV) promoter, can result in expression of the transgene in organs other than the heart. This study tested if the efficiency and specificity of cardiac transcription from a chicken cardiac troponin T (TnT) promoter could be further increased by incorporating a cardiomyocyte-specific transcriptional cis-regulatory motif from human calsequestrin 2 (CS-CRM4) into the expression cassette (Enh.TnT). The efficiency of luciferase expression from the TnT and Enh.TnT constructs was compared to expression of luciferase under the control of the CMV promoter in both adult and neonatal mice. Overall, expression levels of luciferase in the heart were similar in mice injected with AAV9.TnT.Luc, AAV9.Enh.TnT.Luc and AAV9.CMV.Luc. In contrast, expression levels of luciferase activity in nontarget organs, including the liver and muscle, was lower in mice injected with the AAV9.TnT.Luc compared to AAV9.CMV.Luc and was negligible with AAV9.Enh.TnT. In neonates, in organs other than the heart, luciferase expression levels were too low to be quantified for all constructs. Taken together, the data show that the AAV9 Enh.TnT constructs drives high levels of expression of the transgene in the myocardium, with insignificant expression in other organs. These properties reduce the risks associated with the AAV9-mediated expression of the therapeutic protein of interest in nontarget organs. The excellent cardiac specificity should allow for the use of higher vector doses than are currently used, which might be essential to achieve the levels of transgene expression necessary for therapeutic benefits. Taken together, the findings suggest that the Enh.TnT transcription unit is a potentially attractive tool for clinical cardiac gene therapy in adults.

AB - Adeno-associated virus serotype 9 (AAV9) is an efficient vector for gene transfer to the myocardium. However, the use of ubiquitous promoters, such as the cytomegalovirus (CMV) promoter, can result in expression of the transgene in organs other than the heart. This study tested if the efficiency and specificity of cardiac transcription from a chicken cardiac troponin T (TnT) promoter could be further increased by incorporating a cardiomyocyte-specific transcriptional cis-regulatory motif from human calsequestrin 2 (CS-CRM4) into the expression cassette (Enh.TnT). The efficiency of luciferase expression from the TnT and Enh.TnT constructs was compared to expression of luciferase under the control of the CMV promoter in both adult and neonatal mice. Overall, expression levels of luciferase in the heart were similar in mice injected with AAV9.TnT.Luc, AAV9.Enh.TnT.Luc and AAV9.CMV.Luc. In contrast, expression levels of luciferase activity in nontarget organs, including the liver and muscle, was lower in mice injected with the AAV9.TnT.Luc compared to AAV9.CMV.Luc and was negligible with AAV9.Enh.TnT. In neonates, in organs other than the heart, luciferase expression levels were too low to be quantified for all constructs. Taken together, the data show that the AAV9 Enh.TnT constructs drives high levels of expression of the transgene in the myocardium, with insignificant expression in other organs. These properties reduce the risks associated with the AAV9-mediated expression of the therapeutic protein of interest in nontarget organs. The excellent cardiac specificity should allow for the use of higher vector doses than are currently used, which might be essential to achieve the levels of transgene expression necessary for therapeutic benefits. Taken together, the findings suggest that the Enh.TnT transcription unit is a potentially attractive tool for clinical cardiac gene therapy in adults.

KW - AAV9

KW - calsequestrin enhancer

KW - cardiac tropism

KW - cardiac-specific cis-regulatory motif

KW - CMV

KW - troponin T

UR - http://www.scopus.com/inward/record.url?scp=85051364832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051364832&partnerID=8YFLogxK

U2 - 10.1089/hum.2017.188

DO - 10.1089/hum.2017.188

M3 - Article

VL - 29

SP - 927

EP - 937

JO - Human Gene Therapy

T2 - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 8

ER -